Physician profile
Joyce Bumgardner
NPI 1497815187
$7,958.06
in general payments reported to CMS, 2019-2025
15 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,668 · 2020: $495 · 2021: $809 · 2022: $899 · 2023: $871 · 2024: $1,192 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,086.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,518.36 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,362.72 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $885.39 | 2019-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $579.52 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Vanda Pharmaceuticals INC. | $563.44 | 2019-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $417.76 | 2019-2024 | Ingrezza |
| Allergan, INC. | $187.46 | 2019-2020 | |
| Abbvie INC. | $147.17 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.49 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.36 | 2024 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $48.01 | 2024 | |
| Indivior INC. | $47.65 | 2019 | |
| Axsome Therapeutics, INC. | $19.00 | 2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $17.35 | 2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $12.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Bumgardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.